Earnings from continuing operations rose to $1.1 billion, or 56 cents a diluted share, from $1 billion, or 50 cents a share, in the year-ago period. Sales from continuing operations for the quarter rose to $4.7 billion from $4.4 billion. According to Thomson Financial/First Call, analysts expected the company to earn 56 cents in the second quarter.
U.S. pharmaceutical sales rose 12%, and international pharmaceutical sales increased 1%. Sales of Taxol, the company's anticancer drug, fell 21% to $325 million. Worldwide sales of Pravachol, a cholesterol-lowering agent, rose 10% to $448 million.
Additionally, Bristol-Myers said it remains comfortable with the consensus earnings estimates of $2.41 a share for the year.